9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)-

Request For Quotation
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- Suppliers list
Company Name: Shanghai Chaolan Chemical Technology Center  
Tel: QQ：65489617 13301690235
Email: Sales@ATKchemical.com
Company Name: ShangHai ChuanQian Chemcial Technique Centre  
Tel: 15869524721
Email: 3525679403@qq.com
Company Name: Bide Pharmatech Ltd.  
Tel: 400-1647117 13681763483
Email: product02@bidepharm.com
Company Name: Wuhan Jingkangen Biomedical Technology Co., Ltd  
Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Email: customer_service@efebio.com

9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- manufacturers

  • IDO1/TDO-IN-4
  • IDO1/TDO-IN-4 pictures
  • $106.00
  • 2026-07-27
  • CAS:461424-21-5
  • Purity: 98.12%
  • Supply Ability: 10g
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- Basic information
Product Name:9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)-
Synonyms:9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)-;IDO1/TDO-IN-4;1-(5-Imidazolyl)-9H-pyrido[3,4-b]indole;1-(1H-Imidazol-5-yl)-9H-pyrido[3,4-b]indole
CAS:461424-21-5
MF:C14H10N4
MW:234.26
EINECS:
Product Categories:
Mol File:461424-21-5.mol
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- Structure
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- Chemical Properties
Boiling point 627.2±40.0 °C(Predicted)
density 1.410±0.06 g/cm3(Predicted)
pka12.79±0.10(Predicted)
form Solid
color Yellow to brown
Safety Information
MSDS Information
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- Usage And Synthesis
UsesIDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and ππ stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders[1].
in vivo

IDO1/TDO-IN-4 (compound 28, i.p., 20 mg/kg, at day 1, 2, 3) rescues LPS-induced neuroinflammation and depressive-like behavior in mice[1].
IDO1/TDO-IN-4 (I.p. or i.v., 20 mg/kg) displays high exposure and a high volume of distribution at the steady state in normal mice[1].

Animal Model:2 mg/kg LPS-induced depressive mice[1]
Dosage:20 mg/kg
Administration:Intraperitoneal injection (i.p.), at day 1, 2, 3.
Result:Attenuated microglial activation significantly.
Decreased inflammatory factors in the hippocampus, such as TNF-α, IL-1β, and iNOS.
Downregulated LPS-induced overexpression of IDO1.
Animal Model:Male C57BL/6J mice (pharmacokinetic assay)[1]
Dosage:20 mg/kg
Administration:Intraperitoneal injection and intravenous injection
Result:Pharmacokinetic profile of IDO1/TDO-IN-4 (compound 28)
pharmacokinetic property T1/2 (h) Tmax (h) Cmax (ng/mL) bioavailability F (%)
i.v./i.p. 2.31/0.770.25 5543.99/387852.55
IC 50IDO1: 3.53 μM (IC50)
References[1] Yu Zhang, et al. B Discovery of 1-(Hetero)aryl-β-carboline Derivatives as IDO1/TDO Dual Inhibitors with Antidepressant Activity. J Med Chem. 2022 Aug 7. DOI:10.1021/acs.jmedchem.2c00677
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- Preparation Products And Raw materials
Tag:9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)-(461424-21-5) Related Product Information
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- NA NA 2-(1H-imidazol-4-yl)pyridine HCl 2-(1H-Imidazol-4-yl)-pyridine Quinoline,2-(2-pyrazinyl)-